Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: A population approach

HIV Medicine

Volumn 10, Issue 9, 2009, Pages 586-589

  Dailly, E ^a,b   Raffi, F ^a   Perre P ^c   Martin, J ^a   Deslandes, G ^a   Jolliet, P ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Universite de Nantes   (France)

^c La Roche sur Yon Hospital   (France)

Author keywords

Darunavir; Nevirapine; Pharmacokinetics

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; AGED; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; SULFONAMIDES;

EID: 70349985052     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00721.x     Document Type: Article

References (13)

1. Lascar M, Cartledge JD. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors. J HIV Ther 2008, 13:40-44.
2. Back D, Sekar V, Hoetelmans RM. Darunavir. Antivir Ther 2008, 13:1-13.
3. Sekar VJ, Lefebvre E, Marien K. Pharmacokinetic interaction between the antiretroviral agents TMC114 and nevirapine in the presence of low-dose ritonavir. . Toronto, Canada, October 2006 [Abstract 956]
4. Sekar VJ, De Pauw M, Mariën K. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther 2007, 12:509-514.
5. Rawizza HE, Sax PE. Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs. AIDS Read 2008, 18:478-479.
6. Dailly E, Raffi F, Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 813:353-358.
7. Moltó J, Valle M, Miranda C. Once- or twice-daily dosing of nevirapine in HIV-infected adults. J Antimicrob Chemother 2008, 62:784-792.
8. Elsherbiny D, Cohen K, Jansson B. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol 2009, 65:71-80.
9. Dailly E, Billaud E, Reliquet V. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naïve of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 2004, 60:343-348.
10. de Vries-Sluijs TE, Dieleman JP, Arts D. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003, 42:599-605.
11. Kappelhoff BS, Huitema AD, van Leth F. Pharmacokinetics of nevirapine. HIV Clin Trials 2005, 6:254-261.
12. de Maat MM, Beijnen JH, Schellens JH. Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine. J Infect 2005, 50:262-264.
13. Yeni P. Pharmacologie des antirétroviraux. Prise en charge des personnes infectées par le VIH. Recommandations du groupe d'experts 2008, 211-225. In, Paris, Médecine-Sciences Flammarion